Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis (2019)

Description: The outcomes, safety and immune reconstitution (IR) of patients with active, treatment refractory MS are presented.

Outcomes: The event-free survival in our MS cohort is significantly greater than other high-efficacy immunosuppressive therapies and similar to other

AHSCT studies despite a more heavily pretreated cohort.